Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Humans Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)

NCT00656370
View directory record Official record
Conditions
Healthy
Interventions
recombinant human hyaluronidase
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Norwalk Vaccine Study

NCT00973284
View directory record Official record
Conditions
Acute Gastroenteritis, Norwalk Virus Infection
Interventions
Norwalk VLP vaccine, mannitol and sucrose, Norwalk virus
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Caffeine on Human Spinal Motoneurons

NCT04891393
View directory record Official record
Conditions
Healthy
Interventions
Coffee, Decaffeinated coffee
Dietary Supplement
Lead sponsor
Temple University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reverse Cholesterol Transport (RCT) Study

NCT01031758
View directory record Official record
Conditions
Healthy
Interventions
3H-Cholesterol
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults

NCT02174978
View directory record Official record
Conditions
Malaria
Interventions
FMP012 with AS01B adjuvant system, P falciparum Controlled Human Malaria Infection (CHMI)
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants

NCT06698926
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-CLS-616, Placebo, Itraconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects

NCT02663687
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
Recombinant human C1 esterase inhibitor, Placebo, SHP623
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)

NCT03351933
View directory record Official record
Conditions
Anti-Hepatitis A Antibody Levels in Heathy Subjects
Interventions
Immune Globulin (Human)
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of S-740792 in Healthy Adult Study Participants

NCT06724978
View directory record Official record
Conditions
Healthy Participants
Interventions
S-740792 Suspension, Midazolam, Placebo, S-740792 Tablet
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects

NCT03234751
View directory record Official record
Conditions
Diabetes
Interventions
Continous IV infusion of Nesiritide, Hyperinsulinemic euglycemic clamp, Placebo
Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
40 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age

NCT00493285
View directory record Official record
Conditions
Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
Interventions
MEDI-534
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 23 Months
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
30
States / cities
Conway, Arkansas • Little Rock, Arkansas • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of STAR-0215 in Healthy Adult Participants

NCT05477160
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV)
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Effects of Endotoxin in Normal Human Volunteers

NCT00001303
View directory record Official record
Conditions
Healthy, Lung Disease, Sepsis, Septic Shock
Interventions
Reference Endotoxin, Inhaled Nitric Oxide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 45 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 23, 2026, 4:56 PM EDT
Not yet recruiting Not applicable Interventional

Mystical Experiences Without Psychedelics and How Integration Improves Well-Being in Adults

NCT07584070
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Guided Invocation for Mystical Experience
Behavioral
Lead sponsor
Baylor University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

NCT02235961
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC9204-0530, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

NCT00521586
View directory record Official record
Conditions
Influenza
Interventions
13 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 59 Years
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
41
States / cities
Chandler, Arizona • Rolling Hills Estates, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old

NCT02035696
View directory record Official record
Conditions
Influenza
Interventions
Trivalent influenza vaccine (TIVc), Trivalent influenza vaccine-licensed
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 48 Months
Enrollment
671 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 23, 2026, 4:56 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)

NCT01299142
View directory record Official record
Conditions
Influenza
Interventions
FGI-101-1A6
Drug
Lead sponsor
Functional Genetics Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2011 · Synced Oct 23, 2026, 4:56 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.

NCT07089836
View directory record Official record
Conditions
Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum, Plasma, Blooddraw, Sexually Transmitted Infection (STI)
Interventions
ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Lancaster, California • Los Angeles, California • North Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

2013/2017 H7N9 Prime-Boost Interval

NCT03589807
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Atlanta, Georgia • Decatur, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers

NCT02185300
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir Pediatric Granules, Dolutegravir Dispersible Tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 23, 2026, 4:56 PM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Timed Aspirin Chronobiome Study

NCT03590821
View directory record Official record
Conditions
Healthy
Interventions
Aspirin 81 mg, Celecoxib 200mg capsule
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Antacids on the Pharmacokinetics of Raltegravir

NCT00944307
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir, antacid
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 23, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Mix and Match With AS03

NCT01317758
View directory record Official record
Conditions
Influenza
Interventions
AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
Drug · Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 23, 2026, 4:56 PM EDT